Dolutegravir intermediate-1

• Description :

  Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV) -1 infection.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/Dolutegravir_intermediate-1.html

• Purity :

  99.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=C(OC)C(C(C(O)=O)=CN1CC(OC)OC)=O)OC

• Molecular Formula :

  C13H17NO8

• Molecular Weight :

  315.28

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Sivaram Prasad, et al. Process for the preparation of dolutegravir . WO 2016125192 A2.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  Store at room temperature, keep dry and cool

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HIV-1

• CAS Number :

  [1335210-23-5]